TEVA
Teva Pharmaceutical Industries Limited
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$36.36
−0.71%Year over year
Reported trailing growth
- Revenue
- +4.1%
- EBITDA
- -12.9%
- EBIT
- +121.8%
- EPS
- +550.0%
- Free cash flow
- +51.5%
- Operating cash flow
- +36.5%
Forward estimates
Based on analyst estimates
- Revenue
- -3.0%
- EBITDA
- +119.2%
- EPS
- +344.9%
Three-year CAGR
- Revenue
- +5.0%
- EBITDA
- +42.0%
- EBIT
- +123.2%
- Net income
- +186.0%
- EPS
- +184.8%
- Free cash flow
- +3.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026